NASDAQ:ADRO

Aduro Biotech (ADRO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$2.28
$14.60
52-Week Range
N/A
Volume
171,500 shs
Average Volume
162,237 shs
Market Capitalization
$236.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADRO stock logo

About Aduro Biotech Stock (NASDAQ:ADRO)

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

ADRO Stock News Headlines

Aduro Clean Technologies Inc Ordinary Shares
PT Adaro Energy Indonesia Tbk
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
PT Adaro Energy Indonesia Tbk ADRO
Bret Jensen
Concord Biotech Ltd
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
Aduro Selected for Shell GameChanger Program
PT Adaro Energy Indonesia Tbk (ADRO.JK)
Adaro Energy
See More Headlines
Receive ADRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/04/2020
Today
4/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADRO
Fax
N/A
Employees
152
Year Founded
N/A

Profitability

Net Income
$-82,370,000.00
Net Margins
-230.92%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$17.26 million
Book Value
$4.07 per share

Miscellaneous

Free Float
N/A
Market Cap
$236.61 million
Optionable
Optionable
Beta
0.40
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Eric L. Dobmeier
    Chairman, President & Chief Executive Officer
  • Alan Glicklich
    Chief Medical Officer
  • Kirk D. Schumacher
    Senior Vice President & General Counsel
  • Tom Frohlich
    Chief Business Officer
  • Noopur Liffick
    VP-Investor Relations & Corporate Communications

ADRO Stock Analysis - Frequently Asked Questions

How were Aduro Biotech's earnings last quarter?

Aduro Biotech, Inc. (NASDAQ:ADRO) issued its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The biotechnology company had revenue of $13.95 million for the quarter, compared to analyst estimates of $8.81 million. Aduro Biotech had a negative trailing twelve-month return on equity of 101.73% and a negative net margin of 230.92%.

What other stocks do shareholders of Aduro Biotech own?
When did Aduro Biotech IPO?

Aduro Biotech (ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

This page (NASDAQ:ADRO) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners